

Daniel Morales

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2424973/publications.pdf>

Version: 2024-02-01

58
papers

1,827
citations

236925

25
h-index

289244

40
g-index

66
all docs

66
docs citations

66
times ranked

3229
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe. <i>Journal of Asthma</i> , 2023, 60, 76-86.	1.7	4
2	Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 495-510.	1.9	32
3	Health conditions in adults with HIV compared with the general population: A population-based cross-sectional analysis. <i>EClinicalMedicine</i> , 2022, 47, 101392.	7.1	15
4	Predictive performance of a competing risk cardiovascular prediction tool CRISK compared to QRISK3 in older people and those with comorbidity: population cohort study. <i>BMC Medicine</i> , 2022, 20, 152.	5.5	9
5	Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET). <i>Drug Safety</i> , 2021, 44, 193-209.	3.2	8
6	Impact of EU regulatory label changes for diclofenac in people with cardiovascular disease in four countries: Interrupted time series regression analysis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1129-1140.	2.4	9
7	Does additional monitoring status increase the reporting of adverse drug reaction? An interrupted time series analysis of EudraVigilance data. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 350-359.	1.9	5
8	Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 482-491.	1.9	3
9	Antithyroid drug use during pregnancy and the risk of birth defects in offspring: systematic review and meta-analysis of observational studies with methodological considerations. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3890-3900.	2.4	14
10	COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. <i>Rheumatology</i> , 2021, 60, SI37-SI50.	1.9	37
11	Implementation of the COVID-19 Vulnerability Index Across an International Network of Health Care Data Sets: Collaborative External Validation Study. <i>JMIR Medical Informatics</i> , 2021, 9, e21547.	2.6	11
12	Commentary: Obstetric oxytocin exposure and risk of attention-deficit hyperactivity disorder and autism spectrum disorder in offspring—case closed. <i>International Journal of Epidemiology</i> , 2021, 50, 457-458.	1.9	0
13	Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience. <i>Pediatrics</i> , 2021, 148, .	2.1	35
14	COVID-19 and disparities affecting ethnic minorities. <i>Lancet, The</i> , 2021, 397, 1684-1685.	13.7	46
15	Effect of competing mortality risks on predictive performance of the QRISK3 cardiovascular risk prediction tool in older people and those with comorbidity: external validation population cohort study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e352-e361.	4.6	24
16	Authors' Reply to Brailon and Martin's Comment on "Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET)". <i>Drug Safety</i> , 2021, 44, 1011-1013.	3.2	0
17	Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom. <i>International Journal of Obesity</i> , 2021, 45, 2347-2357.	3.4	20
18	Intolerance to Angiotensin Converting Enzyme Inhibitors in Asthma and the General Population: A UK Population-Based Cohort Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3431-3439.e4.	3.8	6

#	ARTICLE	IF	CITATIONS
19	Impact of medicines regulatory risk communications in the UK on prescribing and clinical outcomes: Systematic review, time series analysis and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 698-710.	2.4	30
20	Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 296-305.	1.9	12
21	Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. <i>Nature Communications</i> , 2020, 11, 5009.	12.8	86
22	Association between hydrochlorothiazide exposure and different incident skin, lip and oral cavity cancers: A series of population-based nested case-control studies. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1336-1345.	2.4	30
23	Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. <i>Lancet Rheumatology</i> , The, 2020, 2, e698-e711.	3.9	117
24	Quinine exposure and the risk of acute kidney injury: a population-based observational study of older people. <i>Age and Ageing</i> , 2020, 49, 1042-1047.	1.6	5
25	Comment on "Hydrochlorothiazide use and the risk of skin cancer in patients with hypertensive disorder: a nationwide retrospective cohort study from Korea". <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1014-1015.	1.7	2
26	Addendum to: Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study. <i>Clinical Drug Investigation</i> , 2019, 39, 591-594.	2.2	6
27	Prescribing patterns of tramadol in adults in IMSA® primary care databases in France and Germany between 1 January 2006 and 30 June 2016. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 707-716.	1.9	11
28	A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1086-1096.	1.9	13
29	Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy. <i>JAMA Neurology</i> , 2019, 76, 827.	9.0	49
30	Effect of withdrawal of fusafungine from the market on prescribing of antibiotics and other alternative treatments in Germany: a pharmacovigilance impact study. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 979-984.	1.9	10
31	Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study. <i>Clinical Drug Investigation</i> , 2019, 39, 205-213.	2.2	51
32	Low uptake of palliative care for COPD patients within primary care in the UK. <i>European Respiratory Journal</i> , 2018, 51, 1701879.	6.7	66
33	External validation of ADO, DOSE, COTE and CODEX at predicting death in primary care patients with COPD using standard and machine learning approaches. <i>Respiratory Medicine</i> , 2018, 138, 150-155.	2.9	24
34	Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 419-433.	2.4	62
35	Challenges in interpreting trends in testing for α 1-antitrypsin deficiency in COPD patients from UK primary care. <i>European Respiratory Journal</i> , 2018, 52, 1801986.	6.7	0
36	Concomitant diagnosis of asthma and COPD: a quantitative study in UK primary care. <i>British Journal of General Practice</i> , 2018, 68, e775-e782.	1.4	31

#	ARTICLE	IF	CITATIONS
37	Response to "Comment on "Measuring the impact of medicines regulatory interventions" systematic review and methodological considerations" by Goedecke <i>et al</i> . British Journal of Clinical Pharmacology, 2018, 84, 2169-2170.	2.4	2
38	Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation. BMJ Open, 2018, 8, e023090.	1.9	40
39	Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations. BMC Medicine, 2018, 16, 6.	5.5	87
40	Indications for Systemic Fluoroquinolone Therapy in Europe and Prevalence of Primary-Care Prescribing in France, Germany and the UK: Descriptive Population-Based Study. Clinical Drug Investigation, 2018, 38, 927-933.	2.2	14
41	Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study. BMC Medicine, 2017, 15, 18.	5.5	67
42	Application of real-time global media monitoring and "derived questions" for enhancing communication by regulatory bodies: the case of human papillomavirus vaccines. BMC Medicine, 2017, 15, 91.	5.5	15
43	Comorbidities in adults with asthma: Population-based cross-sectional analysis of 1.4 million adults in Scotland. Clinical and Experimental Allergy, 2017, 47, 1246-1252.	2.9	55
44	Validation of asthma recording in the Clinical Practice Research Datalink (CPRD). BMJ Open, 2017, 7, e017474.	1.9	76
45	Respiratory effect of beta-blocker eye drops in asthma: population-based study and meta-analysis of clinical trials. British Journal of Clinical Pharmacology, 2016, 82, 814-822.	2.4	42
46	Metal Organic Framework as a Potential Drug Carrier for Pulmonary Arterial Hypertension. , 2016, , .		0
47	NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 828-835.	5.7	62
48	Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. Kidney International, 2015, 88, 396-403.	5.2	158
49	Initiating beta-blockers in patients with asthma. The Prescriber, 2014, 25, 9-10.	0.3	2
50	Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials. Journal of Allergy and Clinical Immunology, 2014, 134, 40-45.e10.	2.9	64
51	Adverse Respiratory Effect of Acute Î²-Blocker Exposure in Asthma. Chest, 2014, 145, 779-786.	0.8	88
52	Impact of clinical trial findings on Bell's palsy management in general practice in the UK 2001-2012: interrupted time series regression analysis. BMJ Open, 2013, 3, e003121.	1.9	50
53	Long-acting Î²-agonist prescribing in people with asthma in primary care: Table 1. Thorax, 2013, 68, 192-194.	5.6	5
54	LABA monotherapy in asthma: an avoidable problem. British Journal of General Practice, 2013, 63, 627-628.	1.4	19

#	ARTICLE	IF	CITATIONS
55	Differential Impact of Two Risk Communications on Antipsychotic Prescribing to People with Dementia in Scotland: Segmented Regression Time Series Analysis 2001â€“2011. PLoS ONE, 2013, 8, e68976.	2.5	37
56	Prescribing of β -adrenoceptor antagonists in asthma: an observational study. Thorax, 2011, 66, 502-507.	5.6	15
57	Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe. Wellcome Open Research, 0, 7, 22.	1.8	0
58	Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe. Wellcome Open Research, 0, 7, 22.	1.8	1